Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?

Executive Summary

Amgen's second quarter beat consensus estimates, but with only a $100m increase in sales and few major growth drivers expected in the near term, earnings growth may not last.


Related Content

EU Filings For Amgen/UCB’s Evenity, iv Relenza From GSK, And A New PRIME Product
Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK
ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma
The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics
Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy
US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request
Response Rates Rule In CGRP Inhibitor Migraine Studies
Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts